Table 3.

IL-12/23 and the effect of weight gain (increased BMI) on drug efficacy.

IL-12/23 Inhibitors	Structure and Mechanism	Effect on BMI/Weight Gain	Influence of BMI on Drug Efficacy	Commentary
Ustekinumab	fully human monoclonal antibody (mAb) that binds specifically to IL-12/IL-23p40	No reported BMI changes following treatment [40]	Pharmacokinetic interactions affecting serum concentration and drug clearance [41] Reduced PASI response rates (efficacy) with mass increase [42,43,44,45]	Could be a better alternative for obese patients; Doubling the dose in individuals weighing more than 100 kg significantly increased efficacy [45,46,47]